Reading and Resources

The following list includes websites and articles with comprehensive information about melanoma.

Treatment Guidelines 

Guidelines Link to guidelines
NCCN Clinical Practice Guidelines. (V1.2023) https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf
ESMO Clinical Practice Guidelines. (2019) https://www.esmo.org/guidelines/guidelines-by-topic/melanoma/cutaneous-melanoma

Glossary of FDA approved drugs for Advanced Melanoma

Generic nameTrade nameLink to prescribing information
AtezolizumabTecentriq®https://www.tecentriq.com/melanoma.html
BinimetinibMektovi®https://www.braftovimektovi.com/
CobimetinibCotellic®https://www.cotellic.com/
DabrafenibTafinlar®https://www.us.tafinlarmekinist.com/
EncorafenibBraftovi®https://www.braftovimektovi.com/
Entrectinib*RozlytrekTMhttps://www.rozlytrek.com/
Interleukin-2Proleukin® (Aldesleukin)https://proleukin.com/
IpilimumabYervoy®https://www.yervoy.com/
Larotectinib*Vitrakvi®https://hcp.vitrakvi-us.com/
NivolumabOpdivo®https://www.opdivo.com/
Nivolumab plus RelatlimabOpdualagTMhttps://www.opdualag.com/
PembrolizumabKeytruda®https://www.keytruda.com/melanoma/
Talimogene laherparepvecImlygic®https://www.imlygic.com/
TrametinibMekinist®https://www.us.tafinlarmekinist.com/
VemurafenibZelboraf®https://www.gene.com/patients/medicines/zelboraf

Ongoing clinical trials and new therapeutics for advanced cutaneous melanoma1

AgentPhaseStudy
Atezolizumab + Bevacizumab2NCT04356729
Atezolizumab + Cobimetinib + Vemurafenib3NCT02908672
Botensilimab2NCT05529316
Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab -or- Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib3NCT02224781
Dabrafenib and/or Trametinib Rollover study4NCT03340506
Encorafenib + Binimetinib3NCT05270044
Encorafenib + Binimetinib + Pembrolizumab3NCT04657991
Fianlimab + Cemiplimab3

3
NCT05352672

NCT05608291
Imiquimod + Pembrolizumab1NCT03276832
Ipilimumab4NCT02068196
Ipilimumab + Imatinib mesylate1NCT01738139
Nivolumab + Ipilimumab3

3

3

3

3
NCT04949113

NCT03068455

NCT02388906

NCT01844505

NCT02599402
Nivolumab + Ipilimumab + GM-CSF2/3NCT02339571
Nivolumab/CMP-001 + Nivolumab2/3NCT04695977
Nivolumab/HBI-8000 + Nivolumab3NCT04674683
Nivolumab + Relatlimab3

3

2/3
NCT05002569

NCT05625399

NCT03470922
Panobinostat + Ipilimumab1NCT02032810
PDR001 + Dabrafenib + Trametinib3NCT02967692
Pembrolizumab + Infliximab2NCT05034536
Pembrolizumab + Lenvatinib3NCT03820986
Pembrolizumab/IO102-IO103 + Pembrolizumab3NCT05155254
PeptiCRAd-1 + Pembrolizumab1NCT05492682
Talimogene laherparepvec (T-VEC) + Nivolumab2NCT04330430
Talimogene laherparepvec (T-VEC) + Pembrolizumab2NCT02965716
Tebentafusp/Tebentafusp + Pembrolizumab2/3NCT05549297
Tislelizumab + Dacarbazine2NCT05466474

Websites

ResourceAddress
AIM at Melanoma Foundationhttps://www.aimatmelanoma.org/
American Cancer Society (ACS). Melanoma Skin Cancerhttps://www.cancer.org/cancer/melanoma-skin-cancer.html
ASCO Cancer.Net. Melanomahttps://www.cancer.net/cancer-types/melanoma
Cancer Support Communityhttps://www.cancersupportcommunity.org/
Caregiver Action Networkhttps://www.caregiveraction.org/
Mayo Clinic. Melanomahttps://www.mayoclinic.org/diseases-conditions/melanoma/symptoms-causes/syc-20374884
MedlinePlus. Melanomahttps://medlineplus.gov/melanoma.html
Melanoma Research Foundationhttps://melanoma.org/
National Cancer Institute. Melanoma Treatment (PDQ®) – Health Professional Versionhttps://www.cancer.gov/types/skin/hp/melanoma-treatment-pdq
National Cancer Institute. New therapies are changing the outlook for advanced melanomahttps://www.cancer.gov/types/skin/research/advanced-melanoma-therapies
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Melanoma: Cutaneous. Version 1.2023https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf
US National Library of Medicine. Clinical Trialshttps://clinicaltrials.gov/

References

  1. US National Library of Medicine. Clinical Trials. https://clinicaltrials.gov/ct2/home
Scroll to Top